Pharmacometrics Strategy Lead | PK/PD & Modeling

Allergan; North Chicago (IL); On-site; USD 150,000 - 210,000; Full time

Job summary

AbbVie in the United States is seeking an Associate Director, Pharmacometrics to lead PMx strategy and deliver analyses across drug development programs. The role provides expert consultancy, shapes PMx methodologies, and partners with CPPM and project teams to drive regulatory-ready deliverables.

The successful candidate will have a PhD or equivalent with extensive PK/PD modeling, strategic leadership, and strong communication to influence cross-functional stakeholders and advance therapeutic

Qualifications

• PhD with 5+ years (or Master with 11+ years) in pharmacometrics or related field.
• Strategic thinker with enterprise view and cross-functional influence.
• Proven track record in PMx modeling, simulation, or PK/PD analyses.
• Strong project management and leadership capabilities.

Responsibilities

• Drive PMx strategy across multiple projects and programs; collaborate with CPPM leadership.
• Ensure quality and accuracy of pharmacometrics deliverables.
• Advise on advanced analytics, ML, and mechanistic modeling?
• Ensure timely PMx regulatory documents and responses to agency comments.
• Represent Pharmacometrics in core team meetings and drive process improvements.

Skills

Pharmacometric modeling

PK/PD analysis

Strategic leadership

Cross-functional collaboration

Regulatory science

Education

PhD in pharmacometrics or related field

MS in statistics/pharmacometrics

Tools

NONMEM

R

Python

Job description

AbbVie in the United States is seeking an Associate Director, Pharmacometrics to lead PMx strategy and deliver analyses across drug development programs. The role provides expert consultancy, shapes PMx methodologies, and partners with CPPM and project teams to drive regulatory-ready deliverables.

The successful candidate will have a PhD or equivalent with extensive PK/PD modeling, strategic leadership, and strong communication to influence cross-functional stakeholders and advance therapeutic